Clinical trials: First Episode Psychosis
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Sleep, Physical Activity
On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial
This study will evaluate a program called On Track for Wellness (OTW) which is being adopted by the Illinois Department of Human Services' Division of Behavioral Health \& Recovery (DBHR) for use in all state-funded early…
- Conditions
- Sleep, Physical Activity, First Episode Psychosis
- Trial name
- OTW (NCT07387705)
- Testing
- On Track for Wellness
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- University of Illinois Chicago
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
First-episode Psychosis
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age.
- Trial name
- PEPAMARKER (NCT05384392)
- Testing
- Recorded interview, Clinical scales, Blood sample
- Where
- 5 sites in France
- Volunteers
- 217 people
- Sponsor
- University Hospital, Brest
First-episode Psychosis, Cannabis Abuse
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
General objective: To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment +…
- Trial name
- NCT02319746
- Testing
- Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse, Psychoeducation
- Where
- Spain
- Volunteers
- 88 people
- Sponsor
- Basque Health Service
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Bipolar Disorder
Integrated Care Including Assertive Community Treatment in Early Psychosis
Improvement of clinical long-term outcome through the implementation of early detection and intervention within a specialized network of integrated care (ACT and hometreatment) for adolescents and young adults with a first…
- Trial name
- ICEP (NCT02037581)
- Testing
- Early detection and Integrated Care, Standard Care
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, First-Episode Psychosis
Using mHealth to Optimize Pharmacotherapy Regimens
This project will use a smartphone technology to improve medication prescribing for individuals with FEP. We will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team…
- Trial name
- NCT04248517
- Testing
- mHealth Intervention
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China.
- Trial name
- NCT01057849
- Testing
- risperidone, olanzapine, Aripiprazole
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University
Psychotic Disorders
A Novel Treatment Approach for Self-Stigma in First Episode Psychosis
Stigma towards mental illness is one of the greatest barriers to functional recovery that people with psychotic disorders face. Internalization of stigma (self-stigma) is associated with increased depressive symptoms, treatment…
- Trial name
- BOOST (NCT03491852)
- Testing
- BOOST Intervention, Waitlist Control
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Queen's University
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Clinical High Risk, Early Psychosis
Digital Strategies to Advance Help-Seeking - Aim 3
This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis.
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Trial name
- NCT06774417
- Testing
- Digital nudge
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Columbia University
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Psychosis
Group Dialectical Behaviour Therapy (DBT) Skills Training for First Episode Psychosis
Psychosis is a serious mental health condition that can affect how a person thinks, feels, and functions in daily life, often making it harder to maintain relationships, continue education, or work.
- Trial name
- NCT07777315
- Testing
- group DBT
- Volunteers
- 32 people
- Sponsor
- Centre for Addiction and Mental Health
Psychotic Episode
Evaluation of the Impact of Case Manager Intervention on the 3-year Psychotic Episode Recurrence Rate in Patients Aged 16 to 30 Years With a First Psychotic Episode.
The study investigators hypothesize that the intervention of case managers specifically trained in case management of early psychosis will change the paradigm of care of a first psychotic episode from the current organization of…
- Trial name
- PEPsy-CM (NCT05116514)
- Testing
- Case management
- Where
- 6 sites in France
- Volunteers
- 256 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Psychoses
Brain Cell Injury in Patients With A First Episode of Psychosis
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences…
- Trial name
- NCT00070889
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
First Episode Psychosis, Schizophrenia, Childhood
Early Psychosis Intervention - Spreading Evidence-based Treatment
Implementation of 'NAVIGATE' in Ontario aims to help youth and emerging adults suffering from a first episode of psychosis. Although Ontario already has early psychosis intervention programs, the team's recent work has identified…
- Conditions
- First Episode Psychosis, Schizophrenia, Childhood, Psychosis, Schizophrenia
- Trial name
- EPI-SET (NCT03919760)
- Testing
- NAVIGATE, Treatment as Usual
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Individuals at Risk of First Episode Psychosis
Culturally Adapted Cognitive Behavior Therapy for Individuals At Risk of First Episode Psychosis
Young people constitute nearly half of Pakistan's population and are highly vulnerable to risk factors for mental illness, including poverty, inequality, abuse, and violence.
- Trial name
- NCT07188597
- Testing
- Cognitive Behavior Therapy for those at risk of first episode psychosis
- Where
- 2 sites in Pakistan
- Volunteers
- 90 people
- Sponsor
- Pakistan Institute of Living and Learning